In addition, treatment with broad-spectrum antibiotics prevented the development of metabolic syndrome, low-grade intestinal inflammation, impaired intestinal barrier function, and normalized insulin tolerance in Batf3-/- mice suggesting that intestinal microbiota are essential in the development of metabolic syndrome and the pro-inflammatory phenotype in Batf3-/- mice. This evidence concerns the gene BATF3 and metabolic syndrome.